These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 21570476)

  • 1. A generic operational strategy to qualify translational safety biomarkers.
    Matheis K; Laurie D; Andriamandroso C; Arber N; Badimon L; Benain X; Bendjama K; Clavier I; Colman P; Firat H; Goepfert J; Hall S; Joos T; Kraus S; Kretschmer A; Merz M; Padro T; Planatscher H; Rossi A; Schneiderhan-Marra N; Schuppe-Koistinen I; Thomann P; Vidal JM; Molac B
    Drug Discov Today; 2011 Jul; 16(13-14):600-8. PubMed ID: 21570476
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Promise of new translational safety biomarkers in drug development and challenges to regulatory qualification.
    Sistare FD; DeGeorge JJ
    Biomark Med; 2011 Aug; 5(4):497-514. PubMed ID: 21861671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trials: from traditional to newer approaches part II.
    Macaluso M; Krams M; Preskorn SH
    J Psychiatr Pract; 2011 Jul; 17(4):277-84. PubMed ID: 21775829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel biomarkers of acute kidney toxicity.
    Goodsaid FM; Blank M; Dieterle F; Harlow P; Hausner E; Sistare F; Thompson A; Vonderscher J
    Clin Pharmacol Ther; 2009 Nov; 86(5):490-6. PubMed ID: 19710639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biomarkers in Clinical Trials--SMi Conference. 23-24 September 2009, London, UK.
    Walker G
    IDrugs; 2009 Nov; 12(11):673-4. PubMed ID: 19844848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From biomarker strategies to biomarker activities and back.
    van Gool AJ; Henry B; Sprengers ED
    Drug Discov Today; 2010 Feb; 15(3-4):121-6. PubMed ID: 19931413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents.
    Dancey JE; Dobbin KK; Groshen S; Jessup JM; Hruszkewycz AH; Koehler M; Parchment R; Ratain MJ; Shankar LK; Stadler WM; True LD; Gravell A; Grever MR;
    Clin Cancer Res; 2010 Mar; 16(6):1745-55. PubMed ID: 20215558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety biomarkers in preclinical development: translational potential.
    Sasseville VG; Mansfield KG; Brees DJ
    Vet Pathol; 2014 Jan; 51(1):281-91. PubMed ID: 24091814
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers in drug development: friend or foe? A personal reflection gained working within oncology.
    Carroll KJ
    Pharm Stat; 2007; 6(4):253-60. PubMed ID: 17351904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of biomarkers.
    Aruoma OI; Bahorun T
    Toxicology; 2010 Dec; 278(2):161-4. PubMed ID: 20888386
    [No Abstract]   [Full Text] [Related]  

  • 11. Effective global drug development strategy for obtaining regulatory approval in Japan in the context of ethnicity-related drug response factors.
    Ichimaru K; Toyoshima S; Uyama Y
    Clin Pharmacol Ther; 2010 Mar; 87(3):362-6. PubMed ID: 20107436
    [No Abstract]   [Full Text] [Related]  

  • 12. The use of mechanistic biomarkers for evaluating investigational CNS compounds in early drug development.
    Soares HD
    Curr Opin Investig Drugs; 2010 Jul; 11(7):795-801. PubMed ID: 20571975
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies.
    Petersen TK; Sørensen P
    Drug Discov Today; 2008 Mar; 13(5-6):240-6. PubMed ID: 18342800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative strategies in drug development: clinical pharmacological aspects.
    Kuhlmann J
    Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers in the drug development process: report from workshop discussions.
    van Gool AJ; Spindler P; Harpur E; Bounous D; Olejniczak K; van de Klundert FA; Haenen B
    Regul Toxicol Pharmacol; 2008 Nov; 52(2):75-6. PubMed ID: 18556099
    [No Abstract]   [Full Text] [Related]  

  • 16. Fit-for-purpose biomarker method validation in anticancer drug development.
    Cummings J; Ward TH; Dive C
    Drug Discov Today; 2010 Oct; 15(19-20):816-25. PubMed ID: 20708097
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarker as a classifier in pharmacogenomics clinical trials: a tribute to 30th anniversary of PSI.
    Wang SJ
    Pharm Stat; 2007; 6(4):283-96. PubMed ID: 17957727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and endpoints of clinical trials in hepatocellular carcinoma.
    Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
    J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Standardized endpoint definitions for Transcatheter Aortic Valve Implantation clinical trials: a consensus report from the Valve Academic Research Consortium.
    Leon MB; Piazza N; Nikolsky E; Blackstone EH; Cutlip DE; Kappetein AP; Krucoff MW; Mack M; Mehran R; Miller C; Morel MA; Petersen J; Popma JJ; Takkenberg JJ; Vahanian A; van Es GA; Vranckx P; Webb JG; Windecker S; Serruys PW
    J Am Coll Cardiol; 2011 Jan; 57(3):253-69. PubMed ID: 21216553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potential surrogate endpoints in cancer research--some considerations and examples.
    Duffy SW; Treasure FP
    Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.